{"success":true,"data":{"pressRelease":{"id":"168007","rtpr_id":"nBw7dzq6a-20261013","ticker":"MEDCL","exchange":"Euronext Paris","all_tickers":["MEDCL"],"title":"Medincell Brings Total Non-Dilutive Financing Secured Since July 2026 to €41.8 Million with an Additional €13.8 Million Loan","author":"Business Wire","published_at":"2026-10-13T17:00:00.322Z","article_body":"Medincell Brings Total Non-Dilutive Financing Secured Since July 2026 to\n€41.8 Million with an Additional €13.8 Million Loan\n\nSince July 2026, Medincell has secured €41.8 million in non-dilutive\nfinancing, repaid 50% of its European Investment Bank (EIB) loan, and extended\nits debt maturity profile through September 2031.\n\nMedincell (Euronext Paris: MEDCL) today announced that it has secured an\nadditional €13.8 million in non-dilutive financing from leading European\ncommercial banks and Bpifrance. This additional financing follows the €28\nmillion in non-dilutive bank financing announced in July 2026, bringing the\ntotal amount of non-dilutive financing secured since July 2026 to €41.8\nmillion.\n\nThe financing has been secured on market terms and does not include any\nequity-linked instruments, resulting in no dilution for existing shareholders.\n\nFinancial Position Snapshot\n\n\n * €84.8 million in cash and cash equivalents as of March 31, 2026\n\n * €41.8 million in non-dilutive financing secured since July 2026, including\nthe financing announced today\n\n * €23.2 million repaid to the EIB in July 2026, including €20 million of\nprincipal – representing 50% of the existing financing facility, plus\nrelated capitalized interest\n\nAbout Medincell\n\nMedincell is a clinical- and commercial-stage innovation-driven\nbiopharmaceutical company developing and licensing long-acting injectable\ntreatments across multiple therapeutic areas. Our innovative treatments are\ndesigned to ensure adherence to medical prescriptions, enhance the\neffectiveness and accessibility of medicines, and reduce their environmental\nimpact.\n\nmedincell.com\n\nUZEDY(®) and WELTRUZA™ are trademarks of Teva Pharmaceuticals.\nMedincell’s BEPO(®) technology is licensed to Teva as SteadyTeq™, a\ntrademark of Teva Pharmaceuticals.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20261013196902/en/\n(https://www.businesswire.com/news/home/20261013196902/en/)\n\nDavid Heuzé \n\nHead of Corporate and Financial Communications, and ESG\n\ndavid.heuze@Medincell.com (mailto:david.heuze@Medincell.com) / +33 (0)6 83 25\n21 86\n\nGrace Kim \n\nChief Strategy Officer, U.S. Finance\n\ngrace.kim@medincell.com (mailto:grace.kim@medincell.com) / +1 (646) 991-4023\n\n\nCopyright Business Wire 2026","article_body_html":"","raw_payload":{"data":{"id":"nBw7dzq6a-20261013","title":"Medincell Brings Total Non-Dilutive Financing Secured Since July 2026 to €41.8 Million with an Additional €13.8 Million Loan","author":"Business Wire","ticker":"MEDCL","created":"2026-10-13T17:00:00.322Z","tickers":["MEDCL"],"exchange":"Euronext Paris","article_body":"Medincell Brings Total Non-Dilutive Financing Secured Since July 2026 to\n€41.8 Million with an Additional €13.8 Million Loan\n\nSince July 2026, Medincell has secured €41.8 million in non-dilutive\nfinancing, repaid 50% of its European Investment Bank (EIB) loan, and extended\nits debt maturity profile through September 2031.\n\nMedincell (Euronext Paris: MEDCL) today announced that it has secured an\nadditional €13.8 million in non-dilutive financing from leading European\ncommercial banks and Bpifrance. This additional financing follows the €28\nmillion in non-dilutive bank financing announced in July 2026, bringing the\ntotal amount of non-dilutive financing secured since July 2026 to €41.8\nmillion.\n\nThe financing has been secured on market terms and does not include any\nequity-linked instruments, resulting in no dilution for existing shareholders.\n\nFinancial Position Snapshot\n\n\n * €84.8 million in cash and cash equivalents as of March 31, 2026\n\n * €41.8 million in non-dilutive financing secured since July 2026, including\nthe financing announced today\n\n * €23.2 million repaid to the EIB in July 2026, including €20 million of\nprincipal – representing 50% of the existing financing facility, plus\nrelated capitalized interest\n\nAbout Medincell\n\nMedincell is a clinical- and commercial-stage innovation-driven\nbiopharmaceutical company developing and licensing long-acting injectable\ntreatments across multiple therapeutic areas. Our innovative treatments are\ndesigned to ensure adherence to medical prescriptions, enhance the\neffectiveness and accessibility of medicines, and reduce their environmental\nimpact.\n\nmedincell.com\n\nUZEDY(®) and WELTRUZA™ are trademarks of Teva Pharmaceuticals.\nMedincell’s BEPO(®) technology is licensed to Teva as SteadyTeq™, a\ntrademark of Teva Pharmaceuticals.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20261013196902/en/\n(https://www.businesswire.com/news/home/20261013196902/en/)\n\nDavid Heuzé \n\nHead of Corporate and Financial Communications, and ESG\n\ndavid.heuze@Medincell.com (mailto:david.heuze@Medincell.com) / +33 (0)6 83 25\n21 86\n\nGrace Kim \n\nChief Strategy Officer, U.S. Finance\n\ngrace.kim@medincell.com (mailto:grace.kim@medincell.com) / +1 (646) 991-4023\n\n\nCopyright Business Wire 2026"},"type":"article","timestamp":"2026-10-13T17:00:00.355525159Z","server_sent_at_ms":1791910800355},"received_at":"2026-10-13T17:00:00.406Z","source_url":"https://www.businesswire.com/news/home/20261013196902/en/"},"analysis":{"id":"156288","press_release_id":"168007","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":[],"eventType":"debt_offering","narrative":"Medincell secured an additional €13.8 million in non-dilutive financing from European commercial banks and Bpifrance, bringing total non-dilutive financing since July 2026 to €41.8 million.\n\nThe financing carries no equity-linked instruments, so existing shareholders face no dilution, and the debt maturity profile is extended through September 2031.\n\nThe company also disclosed €84.8 million in cash as of March 31, 2026 and a €23.2 million repayment to the EIB covering 50% of that facility, strengthening its balance sheet position.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Non-dilutive funding stack builds to €41.8M with EIB loan half repaid -- balance-sheet de-risking without shareholder dilution."},"keyFigures":{"customDimensions":{"new_loan":"€13.8 million","eib_repayment":"€23.2 million (including €20 million principal, 50% of facility)","cash_and_equivalents":"€84.8 million as of March 31, 2026","debt_maturity_extended_to":"September 2031","total_non_dilutive_financing":"€41.8 million"}},"namedEntities":{"people":[{"name":"David Heuzé","role":"Head of Corporate and Financial Communications, and ESG"},{"name":"Grace Kim","role":"Chief Strategy Officer, U.S. Finance"}],"products":["UZEDY","WELTRUZA","BEPO","SteadyTeq"],"companies":[{"name":"Medincell","ticker":"MEDCL","relationship":"filer"},{"name":"European Investment Bank (EIB)","relationship":"lender"},{"name":"Bpifrance","relationship":"lender"},{"name":"Teva Pharmaceuticals","relationship":"licensing partner"}],"dollarAmounts":[{"amount":"€13.8 million","context":"additional non-dilutive loan secured"},{"amount":"€41.8 million","context":"total non-dilutive financing secured since July 2026"},{"amount":"€28 million","context":"non-dilutive bank financing announced in July 2026"},{"amount":"€84.8 million","context":"cash and cash equivalents as of March 31, 2026"},{"amount":"€23.2 million","context":"repaid to EIB in July 2026"},{"amount":"€20 million","context":"EIB principal repaid"}]},"materialImpact":{"score":2,"reasoning":"An incremental €13.8M non-dilutive bank facility that extends maturities to 2031 and includes 50% repayment of the EIB loan. Positive for the balance sheet but a routine financing update with no immediate earnings impact."},"tickerRelevance":{"others":[],"primary":"MEDCL"},"globalImportance":22,"audienceRelevance":18,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","crossListed":"Euronext Paris","dilutionRisk":"none","eventGravity":"routine financing update"}},"event_type":"debt_offering","event_type_secondary":null,"sentiment":"bullish","material_impact_score":2,"narrative":"Medincell secured an additional €13.8 million in non-dilutive financing from European commercial banks and Bpifrance, bringing total non-dilutive financing since July 2026 to €41.8 million.\n\nThe financing carries no equity-linked instruments, so existing shareholders face no dilution, and the debt maturity profile is extended through September 2031.\n\nThe company also disclosed €84.8 million in cash as of March 31, 2026 and a €23.2 million repayment to the EIB covering 50% of that facility, strengthening its balance sheet position.","key_figures":{"customDimensions":{"new_loan":"€13.8 million","eib_repayment":"€23.2 million (including €20 million principal, 50% of facility)","cash_and_equivalents":"€84.8 million as of March 31, 2026","debt_maturity_extended_to":"September 2031","total_non_dilutive_financing":"€41.8 million"}},"named_entities":{"people":[{"name":"David Heuzé","role":"Head of Corporate and Financial Communications, and ESG"},{"name":"Grace Kim","role":"Chief Strategy Officer, U.S. Finance"}],"products":["UZEDY","WELTRUZA","BEPO","SteadyTeq"],"companies":[{"name":"Medincell","ticker":"MEDCL","relationship":"filer"},{"name":"European Investment Bank (EIB)","relationship":"lender"},{"name":"Bpifrance","relationship":"lender"},{"name":"Teva Pharmaceuticals","relationship":"licensing partner"}],"dollarAmounts":[{"amount":"€13.8 million","context":"additional non-dilutive loan secured"},{"amount":"€41.8 million","context":"total non-dilutive financing secured since July 2026"},{"amount":"€28 million","context":"non-dilutive bank financing announced in July 2026"},{"amount":"€84.8 million","context":"cash and cash equivalents as of March 31, 2026"},{"amount":"€23.2 million","context":"repaid to EIB in July 2026"},{"amount":"€20 million","context":"EIB principal repaid"}]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-13T17:00:06.028Z","global_importance":22,"audience_relevance":18,"importance_components":{"tickerTier":"small-cap","crossListed":"Euronext Paris","dilutionRisk":"none","eventGravity":"routine financing update"}},"durationMs":5564,"modelName":"glm-5.3-flashx"}}